1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 DNA 1.2.3 RNA 1.2.4 Others 1.3 Market by Application 1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Mild Symptom Patient 1.3.3 Critically Ill Patient 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Perspective (2018-2029) 2.2 Global Novel Coronavirus (COVID-19) Vaccine Growth Trends by Region 2.2.1 Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Region (2018-2023) 2.2.3 Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2024-2029) 2.3 Novel Coronavirus (COVID-19) Vaccine Market Dynamics 2.3.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends 2.3.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers 2.3.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges 2.3.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Novel Coronavirus (COVID-19) Vaccine by Players 3.1.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2018-2023) 3.1.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Players (2018-2023) 3.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio 3.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2022 3.5 Global Key Players of Novel Coronavirus (COVID-19) Vaccine Head office and Area Served 3.6 Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Product and Application 3.7 Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Type 4.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Type (2018-2023) 4.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2029) 5 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Application 5.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Application (2018-2023) 5.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029) 6.2 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type 6.2.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) 6.2.2 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) 6.2.3 North America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) 6.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application 6.3.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) 6.3.2 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) 6.3.3 North America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) 6.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country 6.4.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) 6.4.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029) 7.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type 7.2.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) 7.2.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) 7.2.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) 7.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application 7.3.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) 7.3.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) 7.3.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) 7.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country 7.4.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) 7.4.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029) 8.2 China Novel Coronavirus (COVID-19) Vaccine Market Size by Type 8.2.1 China Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) 8.2.2 China Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) 8.2.3 China Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) 8.3 China Novel Coronavirus (COVID-19) Vaccine Market Size by Application 8.3.1 China Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) 8.3.2 China Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) 8.3.3 China Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029) 9.2 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Type 9.2.1 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) 9.2.2 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) 9.2.3 Asia Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) 9.3 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Application 9.3.1 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) 9.3.2 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) 9.3.3 Asia Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) 9.4 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region 9.4.1 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) 9.4.3 Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Type 10.2.1 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Application 10.3.1 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country 10.4.1 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Inovio Pharmaceuticals 11.1.1 Inovio Pharmaceuticals Company Details 11.1.2 Inovio Pharmaceuticals Business Overview 11.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction 11.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.1.5 Inovio Pharmaceuticals Recent Developments 11.2 Takis Biotech (Evvivax) 11.2.1 Takis Biotech (Evvivax) Company Details 11.2.2 Takis Biotech (Evvivax) Business Overview 11.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction 11.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.2.5 Takis Biotech (Evvivax) Recent Developments 11.3 Zydus Cadila 11.3.1 Zydus Cadila Company Details 11.3.2 Zydus Cadila Business Overview 11.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction 11.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.3.5 Zydus Cadila Recent Developments 11.4 Codagenix, Inc. 11.4.1 Codagenix, Inc. Company Details 11.4.2 Codagenix, Inc. Business Overview 11.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 11.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.4.5 Codagenix, Inc. Recent Developments 11.5 GeoVax, Inc. 11.5.1 GeoVax, Inc. Company Details 11.5.2 GeoVax, Inc. Business Overview 11.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 11.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.5.5 GeoVax, Inc. Recent Developments 11.6 Bravovax 11.6.1 Bravovax Company Details 11.6.2 Bravovax Business Overview 11.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction 11.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.6.5 Bravovax Recent Developments 11.7 Janssen Pharmaceutical Companies 11.7.1 Janssen Pharmaceutical Companies Company Details 11.7.2 Janssen Pharmaceutical Companies Business Overview 11.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction 11.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.7.5 Janssen Pharmaceutical Companies Recent Developments 11.8 Altimmune 11.8.1 Altimmune Company Details 11.8.2 Altimmune Business Overview 11.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction 11.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.8.5 Altimmune Recent Developments 11.9 Vaxart 11.9.1 Vaxart Company Details 11.9.2 Vaxart Business Overview 11.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction 11.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.9.5 Vaxart Recent Developments 11.10 CanSino Biologics 11.10.1 CanSino Biologics Company Details 11.10.2 CanSino Biologics Business Overview 11.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction 11.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.10.5 CanSino Biologics Recent Developments 11.11 ExpreS2ion Biotechnologies ApS 11.11.1 ExpreS2ion Biotechnologies ApS Company Details 11.11.2 ExpreS2ion Biotechnologies ApS Business Overview 11.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction 11.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.11.5 ExpreS2ion Biotechnologies ApS Recent Developments 11.12 Clover Biopharmaceuticals 11.12.1 Clover Biopharmaceuticals Company Details 11.12.2 Clover Biopharmaceuticals Business Overview 11.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction 11.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.12.5 Clover Biopharmaceuticals Recent Developments 11.13 GSK 11.13.1 GSK Company Details 11.13.2 GSK Business Overview 11.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction 11.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.13.5 GSK Recent Developments 11.14 Vaxil Bio Ltd. 11.14.1 Vaxil Bio Ltd. Company Details 11.14.2 Vaxil Bio Ltd. Business Overview 11.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction 11.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.14.5 Vaxil Bio Ltd. Recent Developments 11.15 Generex 11.15.1 Generex Company Details 11.15.2 Generex Business Overview 11.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction 11.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.15.5 Generex Recent Developments 11.16 Novavax, Inc. 11.16.1 Novavax, Inc. Company Details 11.16.2 Novavax, Inc. Business Overview 11.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 11.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.16.5 Novavax, Inc. Recent Developments 11.17 Sanofi Pasteur 11.17.1 Sanofi Pasteur Company Details 11.17.2 Sanofi Pasteur Business Overview 11.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction 11.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.17.5 Sanofi Pasteur Recent Developments 11.18 Baylor 11.18.1 Baylor Company Details 11.18.2 Baylor Business Overview 11.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction 11.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.18.5 Baylor Recent Developments 11.19 iBio, Inc. 11.19.1 iBio, Inc. Company Details 11.19.2 iBio, Inc. Business Overview 11.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 11.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.19.5 iBio, Inc. Recent Developments 11.20 Moderna, Inc. 11.20.1 Moderna, Inc. Company Details 11.20.2 Moderna, Inc. Business Overview 11.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 11.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.20.5 Moderna, Inc. Recent Developments 11.21 Curevac 11.21.1 Curevac Company Details 11.21.2 Curevac Business Overview 11.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction 11.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.21.5 Curevac Recent Developments 11.22 ImmunoPrecise 11.22.1 ImmunoPrecise Company Details 11.22.2 ImmunoPrecise Business Overview 11.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction 11.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) 11.22.5 ImmunoPrecise Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029 Table 2. Key Players of DNA Table 3. Key Players of RNA Table 4. Key Players of Others Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029 Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million) Table 8. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2023) Table 9. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2024-2029) Table 11. Novel Coronavirus (COVID-19) Vaccine Market Trends Table 12. Novel Coronavirus (COVID-19) Vaccine Market Drivers Table 13. Novel Coronavirus (COVID-19) Vaccine Market Challenges Table 14. Novel Coronavirus (COVID-19) Vaccine Market Restraints Table 15. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2018-2023) & (US$ Million) Table 16. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players (2018-2023) Table 17. Global Top Novel Coronavirus (COVID-19) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2022) Table 18. Global Novel Coronavirus (COVID-19) Vaccine Industry Ranking 2021 VS 2022 VS 2023 Table 19. Global 5 Largest Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue (CR5 and HHI) & (2018-2023) Table 20. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Headquarters and Area Served Table 21. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Product and Application Table 22. Global Key Players of Novel Coronavirus (COVID-19) Vaccine, Product and Application Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 25. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2023) Table 26. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 27. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2024-2029) Table 28. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 29. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application (2018-2023) Table 30. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 31. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application (2024-2029) Table 32. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 33. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (US$ Million) Table 34. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 35. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (US$ Million) Table 36. North America Novel Coronavirus (COVID-19) Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 Table 37. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million) Table 38. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) & (US$ Million) Table 39. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 40. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (US$ Million) Table 41. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 42. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (US$ Million) Table 43. Europe Novel Coronavirus (COVID-19) Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 Table 44. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million) Table 45. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) & (US$ Million) Table 46. China Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 47. China Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (US$ Million) Table 48. China Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 49. China Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (US$ Million) Table 50. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 51. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (US$ Million) Table 52. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 53. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (US$ Million) Table 54. Asia Novel Coronavirus (COVID-19) Vaccine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029 Table 55. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million) Table 56. Asia Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2024-2029) & (US$ Million) Table 57. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million) Table 58. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (US$ Million) Table 59. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million) Table 60. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (US$ Million) Table 61. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029 Table 62. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million) Table 63. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2029) & (US$ Million) Table 64. Inovio Pharmaceuticals Company Details Table 65. Inovio Pharmaceuticals Business Overview Table 66. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Table 67. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 68. Inovio Pharmaceuticals Recent Developments Table 69. Takis Biotech (Evvivax) Company Details Table 70. Takis Biotech (Evvivax) Business Overview Table 71. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Table 72. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 73. Takis Biotech (Evvivax) Recent Developments Table 74. Zydus Cadila Company Details Table 75. Zydus Cadila Business Overview Table 76. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Table 77. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 78. Zydus Cadila Recent Developments Table 79. Codagenix, Inc. Company Details Table 80. Codagenix, Inc. Business Overview Table 81. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 82. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 83. Codagenix, Inc. Recent Developments Table 84. GeoVax, Inc. Company Details Table 85. GeoVax, Inc. Business Overview Table 86. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 87. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 88. GeoVax, Inc. Recent Developments Table 89. Bravovax Company Details Table 90. Bravovax Business Overview Table 91. Bravovax Novel Coronavirus (COVID-19) Vaccine Product Table 92. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 93. Bravovax Recent Developments Table 94. Janssen Pharmaceutical Companies Company Details Table 95. Janssen Pharmaceutical Companies Business Overview Table 96. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Table 97. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 98. Janssen Pharmaceutical Companies Recent Developments Table 99. Altimmune Company Details Table 100. Altimmune Business Overview Table 101. Altimmune Novel Coronavirus (COVID-19) Vaccine Product Table 102. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 103. Altimmune Recent Developments Table 104. Vaxart Company Details Table 105. Vaxart Business Overview Table 106. Vaxart Novel Coronavirus (COVID-19) Vaccine Product Table 107. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 108. Vaxart Recent Developments Table 109. CanSino Biologics Company Details Table 110. CanSino Biologics Business Overview Table 111. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Table 112. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 113. CanSino Biologics Recent Developments Table 114. ExpreS2ion Biotechnologies ApS Company Details Table 115. ExpreS2ion Biotechnologies ApS Business Overview Table 116. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Table 117. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 118. ExpreS2ion Biotechnologies ApS Recent Developments Table 119. Clover Biopharmaceuticals Company Details Table 120. Clover Biopharmaceuticals Business Overview Table 121. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Table 122. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 123. Clover Biopharmaceuticals Recent Developments Table 124. GSK Company Details Table 125. GSK Business Overview Table 126. GSK Novel Coronavirus (COVID-19) Vaccine Product Table 127. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 128. GSK Recent Developments Table 129. Vaxil Bio Ltd. Company Details Table 130. Vaxil Bio Ltd. Business Overview Table 131. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Table 132. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 133. Vaxil Bio Ltd. Recent Developments Table 134. Generex Company Details Table 135. Generex Business Overview Table 136. Generex Novel Coronavirus (COVID-19) Vaccine Product Table 137. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 138. Generex Recent Developments Table 139. Novavax, Inc. Company Details Table 140. Novavax, Inc. Business Overview Table 141. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 142. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 143. Novavax, Inc. Recent Developments Table 144. Sanofi Pasteur Company Details Table 145. Sanofi Pasteur Business Overview Table 146. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Table 147. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 148. Sanofi Pasteur Recent Developments Table 149. Baylor Company Details Table 150. Baylor Business Overview Table 151. Baylor Novel Coronavirus (COVID-19) Vaccine Product Table 152. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 153. Baylor Recent Developments Table 154. iBio, Inc. Company Details Table 155. iBio, Inc. Business Overview Table 156. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 157. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 158. iBio, Inc. Recent Developments Table 159. Moderna, Inc. Company Details Table 160. Moderna, Inc. Business Overview Table 161. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 162. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 163. Moderna, Inc. Recent Developments Table 164. Curevac Company Details Table 165. Curevac Business Overview Table 166. Curevac Novel Coronavirus (COVID-19) Vaccine Product Table 167. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 168. Curevac Recent Developments Table 169. ImmunoPrecise Company Details Table 170. ImmunoPrecise Business Overview Table 171. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Table 172. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million) Table 173. ImmunoPrecise Recent Developments Table 174. Research Programs/Design for This Report Table 175. Key Data Information from Secondary Sources Table 176. Key Data Information from Primary Sources List of Figures Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million) Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type: 2022 VS 2029 Figure 3. DNA Features Figure 4. RNA Features Figure 5. Others Features Figure 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million) Figure 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application: 2022 VS 2029 Figure 8. Mild Symptom Patient Case Studies Figure 9. Critically Ill Patient Case Studies Figure 10. Novel Coronavirus (COVID-19) Vaccine Report Years Considered Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region: 2022 VS 2029 Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2022 Figure 15. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2022) Figure 16. The Top 10 and 5 Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue in 2022 Figure 17. North America Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 18. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) Figure 19. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) Figure 20. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2029) Figure 21. United States Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Canada Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Novel Coronavirus (COVID-19) Vaccine Market Size YoY (2018-2029) & (US$ Million) Figure 24. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) Figure 25. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) Figure 26. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2029) Figure 27. Germany Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. France Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. U.K. Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Italy Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Russia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. Nordic Countries Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. China Novel Coronavirus (COVID-19) Vaccine Market Size YoY (2018-2029) & (US$ Million) Figure 34. China Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) Figure 35. China Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) Figure 36. Asia Novel Coronavirus (COVID-19) Vaccine Market Size YoY (2018-2029) & (US$ Million) Figure 37. Asia Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) Figure 38. Asia Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) Figure 39. Asia Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2029) Figure 40. Japan Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. South Korea Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. China Taiwan Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. India Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 45. Australia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Size YoY (2018-2029) & (US$ Million) Figure 47. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2018-2029) Figure 48. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2018-2029) Figure 49. Middle East, Africa, and Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2029) Figure 50. Brazil Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 51. Mexico Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 52. Turkey Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 53. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 54. Israel Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 55. GCC Countries Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2029) & (US$ Million) Figure 56. Inovio Pharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 57. Takis Biotech (Evvivax) Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 58. Zydus Cadila Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 59. Codagenix, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 60. GeoVax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 61. Bravovax Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 62. Janssen Pharmaceutical Companies Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 63. Altimmune Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 64. Vaxart Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 65. CanSino Biologics Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 66. ExpreS2ion Biotechnologies ApS Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 67. Clover Biopharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 68. GSK Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 69. Vaxil Bio Ltd. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 70. Generex Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 71. Novavax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 72. Sanofi Pasteur Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 73. Baylor Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 74. iBio, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 75. Moderna, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 76. Curevac Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 77. ImmunoPrecise Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) Figure 78. Bottom-up and Top-down Approaches for This Report Figure 79. Data Triangulation Figure 80. Key Executives Interviewed

Inovio Pharmaceuticals Takis Biotech (Evvivax) Zydus Cadila Codagenix, Inc. GeoVax, Inc. Bravovax Janssen Pharmaceutical Companies Altimmune Vaxart CanSino Biologics ExpreS2ion Biotechnologies ApS Clover Biopharmaceuticals GSK Vaxil Bio Ltd. Generex Novavax, Inc. Sanofi Pasteur Baylor iBio, Inc. Moderna, Inc. Curevac ImmunoPrecise